171 related articles for article (PubMed ID: 35187419)
1. Second-Generation Prostaglandin Receptor EP2 Antagonist, TG8-260, with High Potency, Selectivity, Oral Bioavailability, and Anti-Inflammatory Properties.
Amaradhi R; Mohammed S; Banik A; Franklin R; Dingledine R; Ganesh T
ACS Pharmacol Transl Sci; 2022 Feb; 5(2):118-133. PubMed ID: 35187419
[TBL] [Abstract][Full Text] [Related]
2. A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in Rats.
Rojas A; Amaradhi R; Banik A; Jiang C; Abreu-Melon J; Wang S; Dingledine R; Ganesh T
Neurotherapeutics; 2021 Apr; 18(2):1207-1225. PubMed ID: 33410110
[TBL] [Abstract][Full Text] [Related]
3. Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties.
Ganesh T; Banik A; Dingledine R; Wang W; Amaradhi R
Mol Pharm; 2018 Dec; 15(12):5809-5817. PubMed ID: 30398879
[TBL] [Abstract][Full Text] [Related]
4. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.
Jiang J; Ganesh T; Du Y; Quan Y; Serrano G; Qui M; Speigel I; Rojas A; Lelutiu N; Dingledine R
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3149-54. PubMed ID: 22323596
[TBL] [Abstract][Full Text] [Related]
5. Novel Microglia Cell Line Expressing the Human EP2 Receptor.
Rojas A; Banik A; Chen D; Flood K; Ganesh T; Dingledine R
ACS Chem Neurosci; 2019 Oct; 10(10):4280-4292. PubMed ID: 31469538
[TBL] [Abstract][Full Text] [Related]
6. Lead optimization studies of cinnamic amide EP2 antagonists.
Ganesh T; Jiang J; Yang MS; Dingledine R
J Med Chem; 2014 May; 57(10):4173-84. PubMed ID: 24773616
[TBL] [Abstract][Full Text] [Related]
7. Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models.
Amaradhi R; Banik A; Mohammed S; Patro V; Rojas A; Wang W; Motati DR; Dingledine R; Ganesh T
J Med Chem; 2020 Feb; 63(3):1032-1050. PubMed ID: 31904232
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
Meja KK; Barnes PJ; Giembycz MA
Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
[TBL] [Abstract][Full Text] [Related]
9. Development of second generation EP2 antagonists with high selectivity.
Ganesh T; Jiang J; Dingledine R
Eur J Med Chem; 2014 Jul; 82():521-35. PubMed ID: 24937185
[TBL] [Abstract][Full Text] [Related]
10. EP
Bradbury P; Rumzhum NN; Ammit AJ
J Cell Physiol; 2019 Jul; 234(7):11070-11077. PubMed ID: 30536718
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide.
Bonfill-Teixidor E; Otxoa-de-Amezaga A; Font-Nieves M; Sans-Fons MG; Planas AM
J Neuroinflammation; 2017 Jan; 14(1):3. PubMed ID: 28086956
[TBL] [Abstract][Full Text] [Related]
12. AH6809 decreases production of inflammatory mediators by PGE
Li P; Jiang H; Wu H; Wu D; Li H; Yu J; Lai J
Brain Res; 2018 Nov; 1698():11-28. PubMed ID: 29792868
[TBL] [Abstract][Full Text] [Related]
13. Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia.
Johansson JU; Pradhan S; Lokteva LA; Woodling NS; Ko N; Brown HD; Wang Q; Loh C; Cekanaviciute E; Buckwalter M; Manning-Bog AB; Andreasson KI
J Neurosci; 2013 Oct; 33(40):16016-32. PubMed ID: 24089506
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus.
Rojas A; Ganesh T; Lelutiu N; Gueorguieva P; Dingledine R
Neuropharmacology; 2015 Jun; 93():15-27. PubMed ID: 25656476
[TBL] [Abstract][Full Text] [Related]
15. The affinity, intrinsic activity and selectivity of a structurally novel EP
Coleman RA; Woodrooffe AJ; Clark KL; Toris CB; Fan S; Wang JW; Woodward DF
Br J Pharmacol; 2019 Mar; 176(5):687-698. PubMed ID: 30341781
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.
Ganesh T
Expert Opin Ther Pat; 2015 Jul; 25(7):837-44. PubMed ID: 25772215
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2.
Fujino H; Salvi S; Regan JW
Mol Pharmacol; 2005 Jul; 68(1):251-9. PubMed ID: 15855407
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Myeloid Cell EP2 Activation Contributes to the Deleterious Consequences of Status Epilepticus.
Varvel NH; Espinosa-Garcia C; Hunter-Chang S; Chen D; Biegel A; Hsieh A; Blackmer-Raynolds L; Ganesh T; Dingledine R
J Neurosci; 2021 Feb; 41(5):1105-1117. PubMed ID: 33293358
[TBL] [Abstract][Full Text] [Related]
19. Activation of EP
Yousif NM; de Oliveira ACP; Brioschi S; Huell M; Biber K; Fiebich BL
Glia; 2018 Apr; 66(4):708-724. PubMed ID: 29226424
[TBL] [Abstract][Full Text] [Related]
20. An Agonist Dependent Allosteric Antagonist of Prostaglandin EP2 Receptors.
Jiang C; Amaradhi R; Ganesh T; Dingledine R
ACS Chem Neurosci; 2020 May; 11(10):1436-1446. PubMed ID: 32324375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
